Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors

US11267820B2 · kind B2 · utility

Assignee

• JUBILANT BIOSYS LIMITED · IN

Inventors

• Saravanan Vadivelu · Bengaluru, IN
• Sridharan Rajagopal · Bengaluru, IN
• Manjunatha M. Ramaiah · Bengaluru, IN
• Pavan Kumar Gondrala · Bengaluru, IN
• Murugan CHINNAPATTU · Bengaluru, IN
• Dhanalakshmi Sivanandhan · Noida, IN
• Payal Kiran Parikh · Bengaluru, IN
• Chandrika Mulakala · Bengaluru, IN

Key dates

• Filing date: May 11, 2020
• Grant date: Mar 8, 2022
• Expiry date: May 11, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure describes heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention, or suppression of diseases, an conditions mediated b one or more BET family of bromodomains.